Findings of Research Misconduct, 2707-2708 [2015-00802]

Download as PDF Federal Register / Vol. 80, No. 12 / Tuesday, January 20, 2015 / Notices any interstate or intrastate telecommunications service. The Commission’s consideration of preemption under section 253 typically begins with the filing of a petition by an aggrieved party. The Commission typically places such petitions on public notice and requests comment by interested parties. The Commission’s decision is based on the public record, generally composed of the petition and comments. The Commission has considered a number of preemption items since the passage of the Telecommunications Act of 1996, and believes it is in the public interest to inform the public of the information necessary for full consideration of the issues likely to be involved in section 253 preemption actions. In order to render a timely and informed decision, the Commission expects petitioners and commenters to provide it with relevant information sufficient to describe the legal regime involved in the controversy and to provide the factual information necessary for a decision. Federal Communications Commission. Marlene H. Dortch, Secretary, Office of the Secretary, Office of the Managing Director. FEDERAL RETIREMENT THRIFT INVESTMENT BOARD Sunshine Act; Notice of Meeting 8:30 a.m. (Eastern Time) January 26, 2015. PLACE: 10th Floor Board Meeting Room, 77 K Street NE., Washington, DC 20002. STATUS: Parts will be open to the public and parts will be closed to the public. MATTERS TO BE CONSIDERED: TIME AND DATE: Open to the Public 1. Approval of the Minutes of the December 15, 2014 Board Member Meeting 2. Leadership Development Program 3. Thrift Savings Plan Reports a. Monthly Participant Activity Report b. Quarterly Investment Policy Report c. Legislative Report d. Vendor Financials e. Audit Status f. Budget Review 4. Annual Expense Ratio Review 5. Project Prioritization Overview 6. Enterprise Risk Assessment 2707 Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows: Facility: Lawrence Livermore National Laboratory. Location: Livermore, California. Job Titles and/or Job Duties: All employees of the Department of Energy, its predecessor agencies, and its contractors and subcontractors who worked in any area. Period of Employment: January 1, 1974 through December 31, 1995. FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS C–46, Cincinnati, OH 45226–1938, Telephone 877–222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV. John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2015–00685 Filed 1–16–15; 8:45 am] BILLING CODE 4163–19–P Closed to the Public 7. Litigation CONTACT PERSON FOR MORE INFORMATION: DEPARTMENT OF HEALTH AND HUMAN SERVICES Kimberly Weaver, Director, Office of External Affairs, (202) 942–1640. Office of the Secretary BILLING CODE 6712–01–P Findings of Research Misconduct FEDERAL ELECTION COMMISSION DATE: January 15, 2015. James Petrick, General Counsel, Federal Retirement Thrift Investment Board. [FR Doc. 2015–00921 Filed 1–15–15; 4:15 pm] SUMMARY: [FR Doc. 2015–00680 Filed 1–16–15; 8:45 am] Sunshine Act Meeting BILLING CODE 6760–01–P AGENCY: Federal Election Commission. Tuesday, January 13, 2015 at 10:00 a.m. and its continuation on Thursday January 15, 2015 at the conclusion of the Open Meeting. DATE AND TIME: PLACE: 999 E Street NW., Washington, DC. This meeting will be closed to the public. STATUS: Federal Register Citation of Previous Announcement—80 FR 1030 (January 8, 2015) rljohnson on DSK3VPTVN1PROD with NOTICES This meeting will be continued on February 10, 2015. * * * * * Judith Ingram, Press Officer, Telephone: (202) 694–1220. [FR Doc. 2015–00905 Filed 1–15–15; 4:15 pm] BILLING CODE 6715–01–P VerDate Sep<11>2014 14:47 Jan 16, 2015 Jkt 235001 Decision to Evaluate a Petition To Designate a Class of Employees From the Lawrence Livermore National Laboratory in Livermore, California, To Be Included in the Special Exposure Cohort National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services. ACTION: Notice. AGENCY: NIOSH gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees from the Lawrence Livermore National Laboratory in Livermore, California, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation SUMMARY: PERSON TO CONTACT FOR INFORMATION: Shelley E. Garr, Deputy Secretary of the Commission. DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Bin Kang, Ph.D., Oklahoma Medical Research Foundation: Based on the Respondent’s admission, an assessment conducted by the Oklahoma Medical Research Foundation (OMRF), and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Bin Kang, Postdoctoral Fellow, Immunobiology and Cancer Research Program, OMRF, engaged in research misconduct in research supported by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grants AI056129 and AI104057. ORI and OMRF found that Respondent engaged in research misconduct by reporting falsified data in: • ‘‘Asb2 regulates the activity of SCF E3 ubiquitin ligases by antagonizing CAND1-mediated exchange of F-box proteins,’’ submitted to Molecular Cell on June 26, 2014; hereafter referred to as the ‘‘original Molecular Cell manuscript’’ E:\FR\FM\20JAN1.SGM 20JAN1 rljohnson on DSK3VPTVN1PROD with NOTICES 2708 Federal Register / Vol. 80, No. 12 / Tuesday, January 20, 2015 / Notices • the revised version of ‘‘Asb2 regulates the activity of SCF E3 ubiquitin ligases by antagonizing CAND1-mediated exchange of F-box proteins,’’ submitted to Molecular Cell on September 29, 2014; hereafter referred to as the ‘‘revised Molecular Cell manuscript • grant application CA189216–01 submitted to the National Cancer Institute (NCI), NIH; hereafter referred to as the ‘‘original NCI grant application’’ • grant application CA189216–01A1 submitted to NCI, NIH; hereafter referred to as the ‘‘revised NCI grant application’’ ORI found that Respondent knowingly falsified and/or fabricated Western blot gel images by duplication, reuse and relabeling, and/or alteration through contrast, rotation, and/or scale of the images. Specifically, Respondent included falsified images in all of the figures (Figures 1–6 and S1–5) in the original Molecular Cell manuscript, all of the figures (Figures 1–6 and S1–7) in the revised Molecular Cell manuscript, Figures 2– 4, 9, and 11 in the original NCI grant application, and Figures 3–5, 10, and 11 in the revised NCI grant application. Dr. Kang has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on December 23, 2014: (1) To have his research supervised; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHSsupported research, the institution employing him must submit a plan for supervision of his duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent’s research contribution; Respondent agreed that he will not participate in any PHSsupported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon plan for supervision; (2) that any institution employing him must submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHSsupported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, VerDate Sep<11>2014 14:47 Jan 16, 2015 Jkt 235001 procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and (3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. Dated: January 13, 2015. E.J. Holland, Jr., Assistant Secretary for Administration (ASA). FOR FURTHER INFORMATION CONTACT: Centers for Medicare & Medicaid Services Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453– 8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2015–00802 Filed 1–16–15; 8:45 am] BILLING CODE 4150–31–P [FR Doc. 2015–00743 Filed 1–16–15; 8:45 am] BILLING CODE 4150–24–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [CMS–3303–FN] Medicare and Medicaid Programs; Continued Approval of the Accreditation Commission for Health Care, Inc.; Home Health Agency Accreditation Program Centers for Medicare and Medicaid Services, HHS. ACTION: Final notice. AGENCY: DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary; Office of Medicare Hearings and Appeals; Statement of Organization, Functions, and Delegations of Authority Part A, Office of the Secretary, Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, is being amended at Chapter AK, Office of Medicare Hearings and Appeals (OMHA), as last amended at 70 FR 36386–36387, dated June 23, 2005, and most recently at 76 FR 19995 (Apr. 11, 2011) as follows: I. Under Section AK.10, Organization, delete the bullets and sub-bullets after the phrase, ‘‘OMHA consists of the following components,’’ and replace with the following: • Medicare Hearings and Appeals Chief Judge’s Office (CJO) (Headquarters Office) — Office of Operations — Office of Programs • Medicare Hearings and Appeals Field Offices II. Under Section AK.20, Functions, Paragraph B, replace ‘‘Medicare Hearings and Appeals Field Offices (AKB1–4)’’ with ‘‘Medicare Hearings and Appeals Field Offices.’’ III. Under Section AK.20, Functions, Paragraph B, ‘‘Medicare Hearings and Appeals Field Offices,’’ replace all references to the ‘‘Managing Administrative Law Judge (MALJ)’’ with ‘‘Associate Chief Administrative Law Judge (ACALJ).’’ PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 This final notice announces our decision to approve the Accreditation Commission for Health Care, Inc., (ACHC) for continued recognition as a national accrediting organization for home health agencies (HHAs) that wish to participate in the Medicare or Medicaid programs. An HHA that participates in Medicaid must also meet the Medicare conditions for participation (CoPs) as required under 42 CFR 488.6(b). DATES: This final notice is effective February 24, 2015 through February 24, 2021. FOR FURTHER INFORMATION CONTACT: Cindy Melanson, (410) 786–0310, or Patricia Chmielewski, (410) 786–6899. SUPPLEMENTARY INFORMATION: SUMMARY: I. Background A healthcare provider may enter into an agreement with Medicare to participate in the program as a HHA provided certain requirements are met. Sections 1861(o) and 1891 of the Social Security Act (the Act), establish distinct criteria for facilities seeking designation as a HHA. Regulations concerning Medicare provider agreements in general are at 42 CFR part 489 and those pertaining to the survey and certification for Medicare participation of providers and certain types of suppliers are at part 488. The regulations at part 484 specify the specific conditions that a provider must meet to participate in the Medicare program as an HHA. Generally, to enter into a Medicare provider agreement, a facility must first be certified as complying with the conditions set forth in part 484 and recommended to us for participation by E:\FR\FM\20JAN1.SGM 20JAN1

Agencies

[Federal Register Volume 80, Number 12 (Tuesday, January 20, 2015)]
[Notices]
[Pages 2707-2708]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-00802]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Bin Kang, Ph.D., Oklahoma Medical Research Foundation: Based on the 
Respondent's admission, an assessment conducted by the Oklahoma Medical 
Research Foundation (OMRF), and additional analysis conducted by ORI in 
its oversight review, ORI found that Dr. Bin Kang, Postdoctoral Fellow, 
Immunobiology and Cancer Research Program, OMRF, engaged in research 
misconduct in research supported by National Institute of Allergy and 
Infectious Diseases (NIAID), National Institutes of Health (NIH), 
grants AI056129 and AI104057.
    ORI and OMRF found that Respondent engaged in research misconduct 
by reporting falsified data in:
     ``Asb2 regulates the activity of SCF E3 ubiquitin ligases 
by antagonizing CAND1-mediated exchange of F-box proteins,'' submitted 
to Molecular Cell on June 26, 2014; hereafter referred to as the 
``original Molecular Cell manuscript''

[[Page 2708]]

     the revised version of ``Asb2 regulates the activity of 
SCF E3 ubiquitin ligases by antagonizing CAND1-mediated exchange of F-
box proteins,'' submitted to Molecular Cell on September 29, 2014; 
hereafter referred to as the ``revised Molecular Cell manuscript
     grant application CA189216-01 submitted to the National 
Cancer Institute (NCI), NIH; hereafter referred to as the ``original 
NCI grant application''
     grant application CA189216-01A1 submitted to NCI, NIH; 
hereafter referred to as the ``revised NCI grant application''
    ORI found that Respondent knowingly falsified and/or fabricated 
Western blot gel images by duplication, reuse and relabeling, and/or 
alteration through contrast, rotation, and/or scale of the images.
    Specifically, Respondent included falsified images in all of the 
figures (Figures 1-6 and S1-5) in the original Molecular Cell 
manuscript, all of the figures (Figures 1-6 and S1-7) in the revised
    Molecular Cell manuscript, Figures 2-4, 9, and 11 in the original 
NCI grant application, and Figures 3-5, 10, and 11 in the revised NCI 
grant application.
    Dr. Kang has entered into a Voluntary Settlement Agreement 
(Agreement) and has voluntarily agreed for a period of three (3) years, 
beginning on December 23, 2014:
    (1) To have his research supervised; Respondent agreed to ensure 
that prior to the submission of an application for U.S. Public Health 
Service (PHS) support for a research project on which the Respondent's 
participation is proposed and prior to Respondent's participation in 
any capacity on PHS-supported research, the institution employing him 
must submit a plan for supervision of his duties to ORI for approval; 
the plan for supervision must be designed to ensure the scientific 
integrity of Respondent's research contribution; Respondent agreed that 
he will not participate in any PHS-supported research until such a 
supervision plan is submitted to and approved by ORI; Respondent agreed 
to maintain responsibility for compliance with the agreed upon plan for 
supervision;
    (2) that any institution employing him must submit, in conjunction 
with each application for PHS funds, or report, manuscript, or abstract 
involving PHS- supported research in which Respondent is involved, a 
certification to ORI that the data provided by Respondent are based on 
actual experiments or are otherwise legitimately derived and that the 
data, procedures, and methodology are accurately reported in the 
application, report, manuscript, or abstract; and
    (3) to exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015-00802 Filed 1-16-15; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.